Tema ETF Trust (CANC)
Management Company · XNAS · Series S000078299 · View on SEC EDGAR ↗
$37.37
As of March 10, 2026
▲ +0.28 (+0.77%)
1-day change
$20.10 – $38.34
52-week range
- Net assets
- $176.1M
- Holdings
- 57
- As of
- May 31, 2026
- Top 10 holdings weight
- 42.86%
- Effective number of positions
- 33.2
- Positions above 1%
- 33
On this page
- Price chart The fund's market price over time, with technical overlays.
- Performance Total return, volatility, drawdown and other risk metrics.
- Fund flows Money flowing in and out of the fund each month, from N-PORT filings.
- Holdings Every position the fund currently holds, with weights.
- Sector breakdown How the fund's holdings split across market sectors.
- Institutional owners 13F institutions that report holding this ETF.
- Similar funds Other funds with overlapping holdings or comparable size.
CANC Stock Price Chart Daily OHLCV with technical indicators — pan, zoom, and customize your view
Configure
Performance as of March 10, 2026
| Period | Price return | Total return |
|---|---|---|
| 1M | ▲ +2.14% | — |
| 3M | ▲ +8.24% | — |
| 6M | ▲ +38.76% | — |
| YTD | ▲ +7.64% | — |
| 1Y | ▲ +50.40% | — |
| 3Y | — | — |
| 5Y | — | — |
| Max since Feb. 27, 2024 | ▲ +28.17% | — |
- Volatility 1Y
- 26.70%
- Volatility 3Y
- —
- Max drawdown 3Y
- —
- Beta 3Y
- —
- Sharpe 1Y*
- 1.68
Total return is shown once dividend history for this fund has been collected — price return alone would duplicate it misleadingly. Returns are not benchmarked against an index. * Sharpe ratio is computed with a 0% risk-free rate.
Fund flows (SEC-reported)
- Last month (May 2026)
- -$2.3M
- Quarter ending May 2026
- +$14.4M
- Trailing 12 months
- +$65.2M
Jun 2025 – May 2026
Based on the fund's own SEC Form N-PORT monthly flow disclosures (Item C.9 "Flow Information") — sales minus redemptions, reinvested distributions excluded. This is a different, independent metric from the "Net flows" estimate above (which is derived from daily shares-outstanding changes). SEC N-PORT filing lag is up to ~60 days; the most recent month/quarter may not yet be fully reflected.
Full composition 57 holdings
| Name | CUSIP | Value | % | Balance | Category | Country |
|---|---|---|---|---|---|---|
| Revolution Medicines Inc | 76155X100 | $13.6M | 7.73 | 86,450 | EC | US |
| Eli Lilly & Co | 532457108 | $8.5M | 4.82 | 7,684 | EC | US |
| Roche Holding AG | 771195104 | $7.4M | 4.21 | 141,653 | EC | CH |
| Cogent Biosciences Inc | 19240Q201 | $7.2M | 4.10 | 206,419 | EC | US |
| Novartis AG | — | $7.1M | 4.03 | 47,020 | EC | CH |
| Immunome Inc | 45257U108 | $6.9M | 3.91 | 315,648 | EC | US |
| Celcuity Inc | 15102K100 | $6.3M | 3.58 | 47,450 | EC | US |
| Merck & Co Inc | 58933Y105 | $6.3M | 3.57 | 52,978 | EC | US |
| AstraZeneca PLC | — | $6.2M | 3.54 | 33,501 | EC | GB |
| Nuvalent Inc | 670703107 | $5.9M | 3.37 | 53,763 | EC | US |
| Bristol-Myers Squibb Co | 110122108 | $5.8M | 3.30 | 101,680 | EC | US |
| Legend Biotech Corp | 52490G102 | $5.3M | 2.99 | 194,092 | EC | US |
| AbbVie Inc | 00287Y109 | $4.9M | 2.81 | 22,700 | EC | US |
| Exelixis Inc | 30161Q104 | $4.9M | 2.78 | 96,885 | EC | US |
| Bridgebio Pharma Inc | 10806X102 | $4.8M | 2.75 | 73,191 | EC | US |
| Johnson & Johnson | 478160104 | $4.5M | 2.55 | 19,900 | EC | US |
| CG oncology Inc | 156944100 | $4.3M | 2.43 | 68,702 | EC | US |
| Genmab A/S | 372303206 | $4.2M | 2.37 | 158,861 | EC | DK |
| Ideaya Biosciences Inc | 45166A102 | $4.0M | 2.27 | 135,847 | EC | US |
| Amgen Inc | 031162100 | $3.7M | 2.11 | 11,019 | EC | US |
| Zai Lab Ltd | 98887Q104 | $3.5M | 1.98 | 196,972 | EC | CN |
| BeOne Medicines Ltd | 07725L102 | $3.3M | 1.88 | 11,505 | EC | US |
| Zymeworks Inc | 98985Y108 | $2.7M | 1.51 | 105,615 | EC | US |
| Enliven Therapeutics Inc | 29337E102 | $2.3M | 1.31 | 58,197 | EC | US |
| Relay Therapeutics Inc | 75943R102 | $2.3M | 1.28 | 161,076 | EC | US |
| Halozyme Therapeutics Inc | 40637H109 | $2.2M | 1.23 | 32,598 | EC | US |
| Summit Therapeutics Inc | 86627T108 | $2.1M | 1.21 | 121,097 | EC | US |
| Arcus Biosciences Inc | 03969F109 | $2.1M | 1.20 | 83,140 | EC | US |
| Gilead Sciences Inc | 375558103 | $2.0M | 1.12 | 14,692 | EC | US |
| Immatics NV | — | $2.0M | 1.12 | 171,499 | EC | DE |
| First American Treasury Obliga | 31846V328 | $1.9M | 1.09 | 1,920,309 | STIV | US |
| Erasca Inc | 29479A108 | $1.9M | 1.08 | 147,828 | EC | US |
| Nuvation Bio Inc | 67080N101 | $1.9M | 1.07 | 395,313 | EC | US |
| AnaptysBio Inc | 032724106 | $1.7M | 0.99 | 31,270 | EC | US |
| UroGen Pharma Ltd | — | $1.6M | 0.93 | 58,518 | EC | US |
| Guardant Health Inc | 40131M109 | $1.4M | 0.81 | 10,986 | EC | US |
| Syndax Pharmaceuticals Inc | 87164F105 | $1.4M | 0.80 | 72,212 | EC | US |
| Corvus Pharmaceuticals Inc | 221015100 | $1.3M | 0.76 | 108,477 | EC | US |
| Regeneron Pharmaceuticals Inc | 75886F107 | $1.3M | 0.75 | 2,138 | EC | US |
| ArriVent Biopharma Inc | 04272N102 | $1.3M | 0.73 | 42,744 | EC | US |
| Chugai Pharmaceutical Co Ltd | — | $1.2M | 0.67 | 23,697 | EC | JP |
| Iovance Biotherapeutics Inc | 462260100 | $1.1M | 0.65 | 280,048 | EC | US |
| Inhibrx Biosciences Inc | 45720N103 | $1.1M | 0.60 | 10,170 | EC | US |
| Olema Pharmaceuticals Inc | 68062P106 | $1.1M | 0.60 | 79,759 | EC | US |
| Cullinan Therapeutics Inc | 230031106 | $1.0M | 0.59 | 62,826 | EC | US |
| Natera Inc | 632307104 | $947K | 0.54 | 4,238 | EC | US |
| First Tracks Biotherapeutics I | 337185102 | $932K | 0.53 | 58,419 | EC | US |
| Immunocore Holdings PLC | 45258D105 | $891K | 0.51 | 30,849 | EC | GB |
| BridgeBio Oncology Therapeutic | 107924102 | $837K | 0.48 | 93,339 | EC | US |
| CytomX Therapeutics Inc | 23284F105 | $824K | 0.47 | 228,987 | EC | US |
Page 1
of 2
← Previous
Next →
Sector breakdown
Healthcare
83.9%
Other/Unmapped
16.1%
Institutional owners (13F) 16 filers
Institutions that report holding this ETF in their quarterly SEC Form 13F. Long positions only; a single filer may appear twice for separate option legs. Large offsetting put/call legs typically reflect market-making or hedged inventory, not directional conviction.
| Institution | Value | % of tracked 13F | Shares | Type | As of |
|---|---|---|---|---|---|
| LPL Financial LLC | $5,725,102 | 31.72% | 138,824 | Shares | June 30, 2026 |
| Willow Financial LLC | $5,124,939 | 28.39% | 139,662 | Shares | March 31, 2026 |
| HighTower Advisors, LLC | $3,150,777 | 17.46% | 76,401 | Shares | June 30, 2026 |
| JANE STREET GROUP, LLC | $1,135,626 | 6.29% | 27,537 | Shares | June 30, 2026 |
| Stratos Wealth Partners, LTD. | $800,180 | 4.43% | 19,403 | Shares | June 30, 2026 |
| Perennial Investment Advisors, LLC | $791,066 | 4.38% | 19,182 | Shares | June 30, 2026 |
| Oder Investment Management, LLC | $511,499 | 2.83% | 12,403 | Shares | June 30, 2026 |
| ROYAL BANK OF CANADA | $299,000 | 1.66% | 7,250 | Shares | June 30, 2026 |
| WJ Wealth Management, LLC | $282,494 | 1.57% | 6,850 | Shares | June 30, 2026 |
| Roxbury Financial LLC | $162,486 | 0.90% | 3,940 | Shares | June 30, 2026 |
| US BANCORP \DE\ | $24,744 | 0.14% | 600 | Shares | June 30, 2026 |
| TD Capital Management LLC | $15,515 | 0.09% | 376 | Shares | June 30, 2026 |
| OSAIC HOLDINGS, INC. | $15,259 | 0.08% | 370 | Shares | June 30, 2026 |
| Thrivent Financial for Lutherans | $7,673 | 0.04% | 186,062 | Shares | June 30, 2026 |
| Integrated Wealth Concepts LLC | $2,681 | 0.01% | 65 | Shares | June 30, 2026 |
| Cambridge Investment Research Advisors, Inc. | $220 | 0.00% | 5,335 | Shares | June 30, 2026 |
Peer funds
Similar by size
| Fund | AUM |
|---|---|
| SDOW ProShares Trust | $176.6M |
| GRNB VanEck ETF Trust | $176.9M |
| POWA Invesco Exchange-Traded Self-In… | $177.0M |
| BITI ProShares Trust | $177.4M |
| LEXI Listed Funds Trust | $179.2M |
| UNHG Themes ETF Trust | $176.1M |
| TMV Direxion Shares ETF Trust | $176.0M |
| XDEC First Trust Exchange-Traded Fun… | $175.3M |
| GXIG Global X Funds | $175.2M |
| XJUN First Trust Exchange-Traded Fun… | $174.9M |